Apretude Kit
Product Images NDC 49702-264

Product Visual Gallery

This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Apretude (NDC 49702-264). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viiv Healthcare Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula Of Cabotegravir (Apretude Spl Graphic 01)

Chemical structure of cabotegravir, the active ingredient in Apretude, showing the arrangement of molecular components including fluorine atoms and ring structures.*

FDA Label Image

Figure 1. Cumulative Incidence Of Hiv-1 Infections In Hptn 083 (Apretude Spl Graphic 02)

A cumulative incidence line graph comparing two drug regimens, Cabotegravir (CAB) and Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), over weeks since randomization. The x-axis shows time in weeks up to 160, and the y-axis shows cumulative incidence. The graph includes a table indicating the number of participants at risk and the number of cumulative events at various week intervals for each regimen.*

FDA Label Image

Figure 2. Cumulative Incidence Of Hiv-1 Infections In Hptn 084 (Apretude Spl Graphic 03)

A cumulative incidence plot showing two treatment groups comparing Cabotegravir (CAB) and Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC). The x-axis represents weeks since randomization, while the y-axis represents cumulative incidence. The graph includes a risk table and cumulative event counts over time for both treatments.*

FDA Label Image

Instructions For Use Header (Apretude Spl Graphic 04)

Instructions for use panel for Apretude (cabotegravir extended-release injectable suspension) showing the strength as 600 mg per 3 mL (200 mg/mL). It specifies the product is for gluteal intramuscular use only and is presented as a 600 mg/3 mL kit.*

FDA Label Image

Storage Information (Apretude Spl Graphic 05)

Apretude kit packaging label showing branding for the human prescription drug Apretude containing cabotegravir. The label features the product name prominently with additional text likely including dosage form details and manufacturer ViiV Healthcare Company. The kit format is indicated on the label.*

FDA Label Image

Kit Contents (Apretude Spl Graphic 06)

Illustration showing components of the Apretude kit by ViiV Healthcare Company, including the Apretude vial with vial cap and rubber stopper, a vial adapter, a syringe with plunger, and an injection needle with needle guard and needle cap.*

FDA Label Image

Figure A (Apretude Spl Graphic 07)

An instructional illustration showing a hand holding a small vial or ampule. A callout highlights the location of the expiration date labeled 'EXP MMM YYYY' on the vial, accompanied by the text 'Check expiration date and medicine.' This image instructs users to verify the medication's expiration date before use.*

FDA Label Image

Figure B (Apretude Spl Graphic 08)

An instructional illustration showing a gloved hand shaking a vial, with repeated motion indicated over 10 seconds, to demonstrate proper mixing or agitation technique for a medication vial labeled Apretude (cabotegravir).*

FDA Label Image

Figure C (Apretude Spl Graphic 09)

An instructional illustration showing hands removing a flip-off cap from the top of a vial. The orange arrow indicates the direction to lift the cap upward. This visual likely relates to the preparation of a medication vial, such as for Apretude cabotegravir kit.*

FDA Label Image

Figure D (Apretude Spl Graphic 10)

Instructional illustration showing hands peeling back the foil cover of a blister pack cavity containing a tablet or injectable vial, demonstrating how to open the packaging for Apretude (Cabotegravir) kit by ViiV Healthcare Company.*

FDA Label Image

Figure E (Apretude Spl Graphic 11)

An instructional illustration showing a gloved hand pressing down and then lifting a flip-top cap on a small vial, demonstrating how to open the container. This image is related to the handling of Apretude (Cabotegravir) kit components.*

FDA Label Image

Figure F (Apretude Spl Graphic 12)

Instructional illustration showing hands holding a syringe with 1 mL of air at the top, indicating to press downward on the plunger. This image is likely part of the administration guide for Apretude (Cabotegravir) Kit by ViiV Healthcare Company.*

FDA Label Image

Figure G (Apretude Spl Graphic 13)

An instructional illustration for using a syringe with a vial, showing hands twisting the syringe plunger in one panel and pushing it downward in the next, indicating the steps to draw or expel medication.*

FDA Label Image

Figure H (Apretude Spl Graphic 14)

An instructional illustration showing a gloved hand holding a syringe prefilled with medication, with an orange arrow pointing downward indicating the action to push or inject. This image likely relates to the use of the Apretude kit containing Cabotegravir for injection.*

FDA Label Image

Figure I (Apretude Spl Graphic 15)

An instructional illustration showing gloved hands drawing liquid from a small vial into a syringe, indicated by orange arrows to demonstrate the rotation and connection process. The image is likely part of preparation steps for an injectable medication kit.*

FDA Label Image

Figure J (Apretude Spl Graphic 16)

An instructional illustration showing gloved hands preparing a syringe by removing a protective cap or seal from a medication vial or ampule, indicated by orange arrows demonstrating the motion. This image is likely part of instructions for using the Apretude kit by ViiV Healthcare Company.*

FDA Label Image

Figure K (Apretude Spl Graphic 17)

An instructional illustration showing a gloved hand positioned near the upper thigh, with markings indicating injection sites on the thigh and hand. This diagram likely demonstrates the proper administration area for an intramuscular injection.*

FDA Label Image

Figure L (Apretude Spl Graphic 18)

An instructional diagram showing a pair of gloved hands unfolding or opening a protective cover from the needle of a syringe. The orange arrow indicates the direction to pull or flip the cover away from the syringe needle.*

FDA Label Image

Figure M (Apretude Spl Graphic 19)

An instructional illustration showing a hand holding a syringe with a needle, indicating to draw up 3 mL of medication. The image highlights the 3 mL mark on the syringe and an upward arrow below the syringe plunger, emphasizing proper measurement or preparation technique.*

FDA Label Image

Figure N (Apretude Spl Graphic 20)

An instructional illustration showing a gloved hand with a marking on the user's skin and an orange arrow indicating a measurement of 1 inch (2.5 cm). The image appears to demonstrate a spacing or placement guideline, likely related to the administration or application of the drug product Apretude (Cabotegravir) kit by ViiV Healthcare Company.*

FDA Label Image

Figure O (Apretude Spl Graphic 21)

An instructional illustration showing a hand pressing down on the plunger of a syringe to administer an injection into the skin, with another hand resting on the injection site. The syringe is shown with the needle inserted at an angle into the skin, indicated by a downward orange arrow over the plunger.*

FDA Label Image

Figure P (Apretude Spl Graphic 22)

Illustration showing a hand holding a syringe being inserted into an applicator or device held by another hand. Purple gloves are worn. An orange arrow above indicates downward motion, suggesting an injection or assembly step.*

FDA Label Image

Figure Q (Apretude Spl Graphic 23)

An instructional illustration showing a hand wearing a purple glove applying or pressing a small adhesive patch onto skin, demonstrating application technique for a transdermal or topical medication.*

FDA Label Image

Figure R (Apretude Spl Graphic 24)

An instructional illustration showing a hand holding a syringe inserting it into a plastic device or vial. The left side depicts the syringe approaching the device with an orange arrow indicating movement, and the right side shows the syringe fully inserted with the word 'click' and lines emphasizing a locking action.*

FDA Label Image

Figure S (Apretude Spl Graphic 25)

An instructional illustration showing a gloved hand holding a syringe with needle, positioned above a sharps disposal container. An orange arrow points downward indicating the syringe should be disposed of into the container labeled 'SHARPS DISPOSAL CONTAINER.'*

FDA Label Image

Apretude 3 mL Kit Carton (Apretude Spl Graphic 26)

Apretude (cabotegravir extended-release injectable suspension) 600 mg/3 mL kit packaging label. The label states it is for gluteal intramuscular use and healthcare professional administration only. Contents include a single-dose vial, vial adapter, syringe, and 23 gauge injection needle. The label features the ViiV Healthcare logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.